NCT02767999

Brief Summary

Fluoxetine action on cerebral connectivity changes in acute ischemic stroke patients

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
25

participants targeted

Target at below P25 for phase_4 stroke

Timeline
Completed

Started Feb 2017

Typical duration for phase_4 stroke

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 6, 2016

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 11, 2016

Completed
10 months until next milestone

Study Start

First participant enrolled

February 27, 2017

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2022

Completed
Last Updated

August 28, 2023

Status Verified

August 1, 2023

Enrollment Period

4.9 years

First QC Date

May 6, 2016

Last Update Submit

August 25, 2023

Conditions

Keywords

Acute ischemic stroke

Outcome Measures

Primary Outcomes (1)

  • Intracerebral connectivity in the motor network between fluoxetine and placebo group.

    Intracerebral connectivity difference in the motor network, assessed by functional resting state MRI, between fluoxetine and placebo group after the treatment.

    90 days

Secondary Outcomes (2)

  • Intracerebral connectivity in the motor network between good responders patients

    90 days

  • Intracerebral connectivity in the motor network between non-responders patients

    90 days

Study Arms (2)

Fluoxetine

EXPERIMENTAL

One group will take a 20 mg of fluoxetine capsule per day from D0 to D90 and have fMRI

Drug: FluoxetineRadiation: fMRI

Placebo

PLACEBO COMPARATOR

The other group will take a cellulose placebo per day from D0 to D90 and have fMRI

Drug: PlaceboRadiation: fMRI

Interventions

20 mg of fluoxetine capsule per day from D0 to D90

Fluoxetine

cellulose placebo per day from D0 to D90

Placebo
fMRIRADIATION

functional resting state MRI

FluoxetinePlacebo

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • First-ever ischemic stroke
  • Cortical or subcortical stroke
  • MRI-proved ischemic stroke

You may not qualify if:

  • pregnant or breast-feeding women
  • alcoholism
  • ongoing Selective Serotonin Reuptake Inhibitor treatment or interruption \< 1 month
  • allergic reaction after SSRI administration
  • MRI contraindication
  • NIHSS\>22
  • Severe aphasia
  • Coma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Hôpital Pellegrin

Bordeaux, France

Location

CHU Toulouse

Toulouse, 31059, France

Location

MeSH Terms

Conditions

StrokeIschemic Stroke

Interventions

Fluoxetine

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

PropylaminesAminesOrganic Chemicals

Study Officials

  • François CHOLLET, MD PhD

    University Hospital, Toulouse

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 6, 2016

First Posted

May 11, 2016

Study Start

February 27, 2017

Primary Completion

January 31, 2022

Study Completion

January 31, 2022

Last Updated

August 28, 2023

Record last verified: 2023-08

Data Sharing

IPD Sharing
Will not share

Locations